Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00712803 · ClinicalTrials.gov registry record · Phase 1

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

A Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
2
Study locations

NCT00712803: Completed Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00712803 is a Phase 1 study of Dengue that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 29 participants, below the 3,978-participant average among 9 other Dengue trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00712803, a Phase 1 study of Dengue, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
2
Study locations

Study Summary

Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a new dengue virus vaccine in healthy adults.

Conditions Studied

Dengue

Interventions

  • BIOLOGICAL rDEN3-3'D4delta30

Study Locations (2)

District of Columbia

  • Center for Immunization Research, Johns Hopkins School of Public Health - Washington D.C.

Maryland

  • Center for Immunization Research, Johns Hopkins University of Public Health - Baltimore

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2008-12
Est. Completion 2009-09
Phase Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00712803 record still lists

NCT00712803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 3,978-participant average among 9 other Dengue trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 1 intervention - of which rDEN3-3'D4delta30 is the first listed.

NCT00712803 reports a single indexed study location in District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT00712803 about?

NCT00712803 is a clinical study titled "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults". Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a new dengue virus vaccine in healthy adults.

What is the current status of trial NCT00712803?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-12. Estimated completion is 2009-09.

What conditions does trial NCT00712803 study?

This clinical trial studies the following conditions: Dengue.

What interventions are being tested in trial NCT00712803?

The interventions under investigation include: rDEN3-3'D4delta30 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00712803?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00712803 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dengue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00712803's enrollment target sits among peer trials

29 8th of 9 higher than 2 of 9 other Dengue trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dengue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00712803, the US trial registry maintained by the National Library of Medicine. NCT00712803 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.